Cancer Immunology – News and Features
News
Bellicum Announces Commercial Licensing of Ariad's ARGENT™
Bellicum announces licensing agreement with Ariad for development of new cancer therapies.
News
Pepscan Secures Euro 7 Million in its Second Financing Round
Company also launches its phase I/II GNRH vaccine trial for the treatment of hormone dependant prostate cancer.
News
Protein Splicing Upsets the DNA Colinearity Paradigm
Study describes a mechanism that extends the number of antigenic peptides that can be produced from a single protein.
News
Debiopharm and Aurigene Enter into Research Agreement
Companies to identify and develop selective compounds for immuno-oncology targets.
News
GSK Licenses Cancer Antigen Portfolio From Ludwig Institute for Cancer Research
GSK has licensed from LICR a significant number of cancer antigens expressed in a large variety of cancers.
News
New Institute for NanoBioTechnology
Johns Hopkins launches institute to apply emerging science to medical problems.
News
Lumera Receives Order from BRI for a ProteomicProcessor Biosensor
Researcher team at Baylor Research Institute plans to use the ProteomicProcessor™ to measure serum protein levels.
News
FDA Grants Biovest International Fast Track Status for BiovaxID™
Biovest is now eligible to submit a biologics license application (BLA) on a rolling basis.
News
Soluble LAG-3 Protein is a Prognostic Factor in Breast Cancer
The results pave the way for the testing of a recombinant sLAG-3 protein as an adjuvant therapy for breast cancer in clinical trials.
News
Eden Biodesign and Onyvax Limited Announce Biomanufacturing Contract
Eden will supply cGMP clinical manufacturing services to Onyvax for its Cell Vaccine program in ovarian cancer.
Advertisement
